PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16983934-0 2006 Effect of hyaluronan and deoxycholate on transperitoneal insulin and albumin transport in vitro. Hyaluronic Acid 10-20 insulin Homo sapiens 57-64 11454516-8 2001 CONCLUSIONS: The present data obtained with human arterial smooth muscle cells in vitro showed that glucose, insulin and hGH can influence the accumulation of hyaluronan and CSPG. Hyaluronic Acid 159-169 insulin Homo sapiens 109-116 16789485-5 2005 The aim of presented studies in vitro was qualification of hyaluronan influence on transport dynamics of the selected macromolecules (albumin 1 g/dL, icodextrin 7.5 g/dL and insulin 0.1 g/dL). Hyaluronic Acid 59-69 insulin Homo sapiens 174-181 34880612-0 2021 Layered Double Hydroxide Modified with Deoxycholic and Hyaluronic Acids for Efficient Oral Insulin Absorption. Hyaluronic Acid 55-71 insulin Homo sapiens 91-98 11732625-3 2001 Insulin and WGA stimulated [3H]glucosamine incorporation into hyaluronic acid (HA) and heparan sulphate (HS) without any alteration of chondroitin sulphate (CS) and dermatan sulphate (DS) contents. Hyaluronic Acid 62-77 insulin Homo sapiens 0-7 11732625-3 2001 Insulin and WGA stimulated [3H]glucosamine incorporation into hyaluronic acid (HA) and heparan sulphate (HS) without any alteration of chondroitin sulphate (CS) and dermatan sulphate (DS) contents. Hyaluronic Acid 79-81 insulin Homo sapiens 0-7 10210724-4 1999 Insulin was preferentially partitioned into the PEG phase in a PEG/HA solution system. Hyaluronic Acid 67-69 insulin Homo sapiens 0-7 34880612-1 2021 Introduction: This study aimed to construct a layered double hydroxide (LDH) nanoparticle delivery system that was modified by deoxycholic acid (DCA) and hyaluronic acid (HA) to increase the bioavailability of oral insulin. Hyaluronic Acid 154-169 insulin Homo sapiens 215-222 34880612-1 2021 Introduction: This study aimed to construct a layered double hydroxide (LDH) nanoparticle delivery system that was modified by deoxycholic acid (DCA) and hyaluronic acid (HA) to increase the bioavailability of oral insulin. Hyaluronic Acid 171-173 insulin Homo sapiens 215-222 34880612-12 2021 Conclusion: LDH nanoparticles modified by DCA and HA improved the absorption efficiency of insulin by opening the TJs of cells and interacting with the cholic acid transporter receptor protein. Hyaluronic Acid 50-52 insulin Homo sapiens 91-98 3551429-9 1987 The results suggest that type I diabetic sera contain factors other than insulin, growth hormone or insulin-like growth factor-I that affect the proliferation and synthesis of hyaluronic acid and collagen of HSMCs in culture. Hyaluronic Acid 176-191 insulin Homo sapiens 100-107 34301147-4 2021 Herein, we have combined all-atom molecular dynamics simulation and coarse-grained dissipative particle dynamics to systematically study insulin"s structural stability and diffusion coefficient in polyvinyl alcohol and hyaluronic acid solutions. Hyaluronic Acid 219-234 insulin Homo sapiens 137-144 34301147-7 2021 Mesoscopic simulation results manifest that the diffusion coefficient of insulin in hyaluronic acid (HA) solution is greater than that of the polyvinyl alcohol (PVA) system. Hyaluronic Acid 84-99 insulin Homo sapiens 73-80 34301147-7 2021 Mesoscopic simulation results manifest that the diffusion coefficient of insulin in hyaluronic acid (HA) solution is greater than that of the polyvinyl alcohol (PVA) system. Hyaluronic Acid 101-103 insulin Homo sapiens 73-80 35182103-2 2022 In the present study, a hyaluronic acid coated chitosan nanoparticle delivery system was fabricated for insulin oral delivery. Hyaluronic Acid 24-39 insulin Homo sapiens 104-111 35182103-5 2022 Hyaluronic acid (HA) was further applied to coat CNP (HCP) to improve stability, reduce enzymatic degradation and promote absorption of insulin. Hyaluronic Acid 0-15 insulin Homo sapiens 136-143 35182103-5 2022 Hyaluronic acid (HA) was further applied to coat CNP (HCP) to improve stability, reduce enzymatic degradation and promote absorption of insulin. Hyaluronic Acid 17-19 insulin Homo sapiens 136-143 30601665-5 2019 Moreover, the addition of hyaluronic acid (HA) in alginate microcapsules enhanced, even more, the insulin release from the final IPCs, independent of the MSC source. Hyaluronic Acid 26-41 insulin Homo sapiens 98-105 32987063-2 2020 This study aimed to assess the faster responsiveness of the insulin release from this enzyme based nanoparticles which is a self-regulated insulin delivery system constructed by loading with insulin, enzyme glucose oxidase into hyaluronic acid and 2-nitroimidazole forming enzyme-based nanoparticles which works in accordance to the blood glucose level. Hyaluronic Acid 228-243 insulin Homo sapiens 60-67 32987063-2 2020 This study aimed to assess the faster responsiveness of the insulin release from this enzyme based nanoparticles which is a self-regulated insulin delivery system constructed by loading with insulin, enzyme glucose oxidase into hyaluronic acid and 2-nitroimidazole forming enzyme-based nanoparticles which works in accordance to the blood glucose level. Hyaluronic Acid 228-243 insulin Homo sapiens 139-146 32987063-2 2020 This study aimed to assess the faster responsiveness of the insulin release from this enzyme based nanoparticles which is a self-regulated insulin delivery system constructed by loading with insulin, enzyme glucose oxidase into hyaluronic acid and 2-nitroimidazole forming enzyme-based nanoparticles which works in accordance to the blood glucose level. Hyaluronic Acid 228-243 insulin Homo sapiens 139-146 30755628-0 2019 Cardiac fibroblast activation and hyaluronan synthesis in response to hyperglycemia and diet-induced insulin resistance. Hyaluronic Acid 34-44 insulin Homo sapiens 101-108 30597265-0 2019 Hyaluronic acid enhances cell survival of encapsulated insulin-producing cells in alginate-based microcapsules. Hyaluronic Acid 0-15 insulin Homo sapiens 55-62 30601665-5 2019 Moreover, the addition of hyaluronic acid (HA) in alginate microcapsules enhanced, even more, the insulin release from the final IPCs, independent of the MSC source. Hyaluronic Acid 43-45 insulin Homo sapiens 98-105 23349492-0 2013 Hyaluronan accumulates with high-fat feeding and contributes to insulin resistance. Hyaluronic Acid 0-10 insulin Homo sapiens 64-71 27612686-5 2016 In order to enhance the oral bioavailability of insulin, the insulin-loaded glucose-responsive nanocarriers were further encapsulated into a three-dimensional (3D) hyaluronic acid (HA) hydrogel environment for overcoming multiple barriers and providing multi-protection for insulin during the transport process. Hyaluronic Acid 164-179 insulin Homo sapiens 61-68 27612686-5 2016 In order to enhance the oral bioavailability of insulin, the insulin-loaded glucose-responsive nanocarriers were further encapsulated into a three-dimensional (3D) hyaluronic acid (HA) hydrogel environment for overcoming multiple barriers and providing multi-protection for insulin during the transport process. Hyaluronic Acid 164-179 insulin Homo sapiens 61-68 29984479-0 2018 Uniform Core-Shell Nanoparticles with Thiolated Hyaluronic Acid Coating to Enhance Oral Delivery of Insulin. Hyaluronic Acid 48-63 insulin Homo sapiens 100-107 29984479-3 2018 Herein, using insulin as a model protein therapeutic, the core-shell nanoparticles with thiolated hyaluronic acid (HA-SH) coating (NPHA-SH ) are produced utilizing a two-step flash nanocomplexation process to enhance oral delivery efficiency of insulin. Hyaluronic Acid 98-113 insulin Homo sapiens 14-21 22644708-0 2012 Insulin-loaded pH-sensitive hyaluronic acid nanoparticles enhance transcellular delivery. Hyaluronic Acid 28-43 insulin Homo sapiens 0-7 23399272-2 2013 Here, the potentials of hyaluronic acid (HA) have been investigated by studying the conjugates with two model enzymes, trypsin and RNase A, and with insulin. Hyaluronic Acid 24-39 insulin Homo sapiens 149-156 23399272-2 2013 Here, the potentials of hyaluronic acid (HA) have been investigated by studying the conjugates with two model enzymes, trypsin and RNase A, and with insulin. Hyaluronic Acid 41-43 insulin Homo sapiens 149-156 22644708-1 2012 In the present study, we developed novel insulin-loaded hyaluronic acid (HA) nanoparticles for insulin delivery. Hyaluronic Acid 56-71 insulin Homo sapiens 41-48 22644708-1 2012 In the present study, we developed novel insulin-loaded hyaluronic acid (HA) nanoparticles for insulin delivery. Hyaluronic Acid 73-75 insulin Homo sapiens 41-48 20148851-0 2010 Hyaluronic acid filler injections with a 31-gauge insulin syringe. Hyaluronic Acid 0-15 insulin Homo sapiens 50-57